Abstract
Introduction Rapid genome sequencing (rGS) provides high diagnostic yield for critically ill infants with suspected genetic disorders, but it has high upfront costs and insufficient insurance coverage. Assessing the long-term costs of rGS is important for guiding coverage decisions. This study compares 1-year healthcare costs for: 1) early rGS (within 7 days of admission) for all infants, and 2) early targeted neonatal gene sequencing (NewbornDx) for all infants, followed by rGS after 7 days for undiagnosed infants.
Methods The Genomic Medicine for Ill Neonates and Infants (GEMINI) study was a multicenter, prospective study that enrolled 400 hospitalized infants under one year with suspected genetic disorders. All participants underwent both rGS and NewbornDx. Using study data, we developed and populated a decision tree to compare 1-year costs for early rGS versus early NewbornDx followed by later rGS if necessary.
Results The diagnostic yield and upfront testing costs were higher for rGS (49%; $12,297) than NewbornDx (27%; $2,449; p<0.05). Over 1 year, early rGS was estimated to save $158,592 per patient (95% CI: $63,701-$253,292) compared to early NewbornDx with later rGS if necessary.
Discussion Early rGS results in substantial cost savings, highlighting the need to expand reimbursement to improve access.
Competing Interest Statement
Dr. Lavelle's work has been funded by grants from Genentech and Merck & Co., and she has received consulting fees from Takeda. Dr. Kingsmore has received grants from Alexion Pharmaceuticals, Amgen, Chiesi Farmaceutici, Horizon Therapeutics, Inozyme Pharmaceuticals, Ionis Pharmaceuticals, Orchard Therapeutics, Rocket Pharmaceuticals, Sanofi S.A., Sarepta Therapeutics, Sentinyl Therapeutics Inc., Travere, and Ultragenyx. Dr. Maron serves on the advisory committee for SimpliFed. Dr. Reed has served as an advisor to Myriad Genetics and Mirvie. Dr. Zhu has received grants from Genentech. All other authors declare no conflict of interest.
Clinical Trial
NCT03890679
Funding Statement
This study was funded by a grant from the National Center for Advancing Translational Sciences (NCATS) (U01TR00271). NCATS had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Johns Hopkins Single Institutional Review Board (IRB; JHUSIRB00000007), which served as the central IRB for all participating institutions in the Genomic Medicine for Ill Neonates and Infants (GEMINI) study. All institutions involved in the research received IRB approval for the study. Informed consent was obtained from all participants or their legal guardians, as required by the IRB. The data collected for this study were de-identified to protect participant confidentiality. The study adhered to the principles outlined in the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data and models are available from the corresponding author upon request.
